An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

Exclusion Criteria

• •Documented cirrhosis after liver transplantation
• •Ascites or hepatic encephalopathy within 6 months before Screening
• •Retransplantation for recurrent hepatitis C
• •Treatment for hepatitis C post liver transplantation
• •History within the past 3 months of: rejection within 3 months or greater than (\>) 1 rejection within 12 months
• •Current treatment with sirolimus or methylprednisolone. Low dose prednisone use (\<5 milligram per day) is permitted
• •History within 3 months of any bacterial infection requiring \>1 week of intravenous antibiotics, cytomegalovirus viremia or cytomegalovirus infection with end-organ involvement, fungal disease (except cutaneous and mild oral thrush)
• •History of post transplant lymphoproliferative disease
• •Acceptable laboratory values at Screening as specified in the protocol
• •Positive for human immunodeficiency virus 1/2 (HIV1/2) enzyme immunoassay (EIA) antibody screen or Hepatitis B deoxyribonucleic acid (DNA) or Hepatitis B surface antigen
• •History of hepatocellular carcinoma with high risk of recurrence
• •Any other cause of liver disease deemed clinically significant by the investigator in addition to hepatitis C
• •Autoimmune-mediated disease
• •History of acute pancreatitis within 5 years before the Screening visit
• •Prior treatment with an hepatitis C virus (HCV) protease inhibitor